HRTS ETF — Tema Cardiovascular and Metabolic ETF

Tema Cardiovascular and Metabolic ETF (HRTS)

Updated October 16, 2026.

HRTS is an ETF. its distribution rate is 1.28%, its trailing-12-month yield is 1.28%, its expense ratio is 0.75%. Dividend Vision Distribution Safety Score™ is 50/100 (Unproven). Total return is 42.6% over the past 2.9 years, 32.0 points behind SPY at 74.6%.

Tema Cardiovascular and Metabolic ETF is an equity fund that invests at least eighty percent of its assets in publicly listed companies deriving at least half their revenues from GLP-1 products, cardiovascular treatments, or metabolic disease therapies; the fund typically holds between fifteen and one hundred companies and is non-diversified. It carries an expense ratio of 0.75% and distributes at a modest rate. The fund appeals to investors seeking exposure to the cardiovascular and metabolic health treatment sectors.

HRTS performance versus SPY

Price and return data through 2026-10-16.

Total return is 42.6% over the past 2.9 years, 32.0 points behind SPY at 74.6%. Over the past year its total return — price change plus distributions reinvested — is 16.4%. Its deepest 1-year drawdown was 11.0%.

HRTS key facts

Distribution Safety Score™

50 · Unproven

Issuer

Tema ETFs

Asset type

ETF

Asset class

Equity

Inception date

11/20/2023

Expense ratio

0.75%

Distribution rate

1.28%

Distribution frequency

Annual

Trailing yield

1.28%

Last close

$36.90 (as of 2026-10-16)

AUM

$53,600,222

Average volume

2357.0

Dividend

$0.473

Ex-dividend date

12/10/2025

Payment date

12/11/2025

How Dividend Vision calculates yield and returns

Distribution rate (1.28%) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield (1.28%) is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: Tema ETFs; prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

HRTS risks and drawbacks

HRTS's current distribution rate is moderate, not a high-yield payout — the strategy is dividend quality more than maximum income. Payments are annual, so cash flow is lumpy versus a monthly fund. Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 11.0%.

Who may consider HRTS — and who may not

It is a weaker fit for investors who need monthly cash flow (HRTS pays annual); investors hunting double-digit covered-call yields; investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on HRTS

• All tickers starting with H

Frequently asked questions

More securities from Tema ETFs.